(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of 34.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Protagonist Therapeutics's revenue in 2024 is $60,000,000.On average, 4 Wall Street analysts forecast PTGX's revenue for 2024 to be $13,767,468,278, with the lowest PTGX revenue forecast at $582,749,980, and the highest PTGX revenue forecast at $19,522,124,330. On average, 4 Wall Street analysts forecast PTGX's revenue for 2025 to be $8,725,224,076, with the lowest PTGX revenue forecast at $2,849,647,402, and the highest PTGX revenue forecast at $19,230,749,340.
In 2026, PTGX is forecast to generate $8,485,597,284 in revenue, with the lowest revenue forecast at $4,580,414,843 and the highest revenue forecast at $15,107,210,482.